Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

New US fill finish facility receives $4.1 billion investment

2
SHARES

Novo Nordisk plans to allocate $6.8 billion towards production to expand its overall US manufacturing capacity.

Novo Nordisk production facility

Plans for new Novo Nordisk production facilities in Clayton, North Carolina, US. Credit: Novo Nordisk

Novo Nordisk has announced one of its largest manufacturing investments; $4.1 billion will support the construction of a second fill and finish facility for aseptic manufacturing in Clayton, North Carolina, US.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The increased capacity will add 1.4 million ft2 of production space, double the combined square footage of all three of the company’s existing facilities in North Carolina.

[the new facility will double] the combined square footage of all three of [Novo Nordisk]’s existing facilities in North Carolina”

Overall, the expansion will support Novo Nordisk’s ability to produce injectable treatments for obesity and other chronic diseases such as diabetes.

The facility is set to incorporate features that support environmental sustainability, such as roof-top solar panels and innovative water strategies, as well as advanced technology, according to Novo Nordisk.

In 2016, the company announced a new facility, the single largest life sciences investment in North Carolina at the time, Butch Lawter, Chair of the Johnston County Board of Commissioners, US, explained during a press conference.

“Clayton was the first manufacturing site for Novo Nordisk in the US, and this new, large-scale investment confirms the continued importance of our production facilities there as cornerstones of our company’s growth,” shared Henrik Wulff, Executive Vice President, Product Supply, Quality & IT, Novo Nordisk.

Novo Nordisk $11b acquisition to support manufacturing capacity

Further details about Novo Nordisk’s new production facility

The investment will also generate 1,000 new jobs. This is in addition to the company’s current workforce in the region, which totals nearly 2,500 employees, the firm stated.

They added that in 2024, it anticipates increasing its actual production investments. In total, it plans to invest approximately $6.8 billion (DKK 45 billion) in production. This is compared to the company’s $3.9 (DKK 26 billion) investment in 2023, not including acquisitions.

Initial construction work has begun on the new facility. Completion is expected between 2027 and 2029. Currently, worldwide, the pharmaceutical company has a five production sites in Denmark, US, France, Brazil and China, the company noted.

Haemophilia drug could reduce treated bleeding episodes…

Share via
Share via